We recommend that you upgrade to the latest version of your browser.

CycloME delA

CycloME part A – a phase II study testing the chemotherapy drug cyclophosphamide in patients with moderate to severe ME/CFS.

A person in a hospital bed

CycloME Part A

The cyclophosphamide study is a single-centre study. The oncology department at HUS is the only study centre that has included patients in Part A. Additionally, the Norwegian Radium Hospital is a treatment centre in the study and has provided treatments to a smaller group of patients residing in the Oslo area.
 
CycloME is a blinded study, so all participants have received treatment with active medication. Each participant has undergone 6 intravenous treatments with a four-week interval and follow-up for 12 months thereafter. Each participant has completed examinations and tests before and after treatment, and systematically reported on their own symptom development.
 
The purpose of the study was to investigate whether treatment with cyclophosphamide can provide clinical improvement and acceptable side effects in patients with ME/CFS.
In Part A, 40 patients with moderate to severe illness participated.

Status of CycloME Part A

Treatment and follow-up in the CycloME study were completed in August 2017.
The results from the study have been published in Frontiers in Medicine. You will find a link to the article in the overview of published articles below.

Last updated 11/17/2026